Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel†

A transition from a subtyping to a phenotyping approach in rosacea is underway, allowing individual patient management according to presenting features instead of categorization by predefined subtypes. The ROSacea COnsensus (ROSCO) 2017 recommendations further support this transition and align with guidance from other working groups.

[1]  Combined doxycycline 40 mg modified release capsules plus ivermectin 1% cream therapy for severe papulopustular rosacea , 2019, Journal of the American Academy of Dermatology.

[2]  Z. Fedorowicz,et al.  Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments† , 2019, The British journal of dermatology.

[3]  M. Steinhoff.  Faculty Opinions recommendation of Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  R. Gallo,et al.  Applying the phenotype approach for rosacea to practice and research , 2018, The British journal of dermatology.

[5]  J. Harper,et al.  Cross-Sectional Survey of the Burden of Illness of Rosacea by Erythema Severity. , 2018, Journal of drugs in dermatology : JDD.

[6]  M. Gooderham,et al.  Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. , 2017, Journal of drugs in dermatology : JDD.

[7]  M. Schaller,et al.  Defining treatment success in rosacea as ‘clear’ may provide multiple patient benefits: results of a pooled analysis , 2017, The Journal of dermatological treatment.

[8]  M. Schaller,et al.  Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel , 2017, The British journal of dermatology.

[9]  M. Schaller,et al.  Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel , 2017, The British journal of dermatology.

[10]  A. Drucker.  Taking steps to improve the assessment and management of rosacea , 2017, The British journal of dermatology.

[11]  P. Peñas,et al.  Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  J. Leyden,et al.  Shortcomings in rosacea diagnosis and classification , 2017, The British journal of dermatology.

[13]  Mohammad A. Al-Amry,et al.  Ocular acne rosacea in tertiary eye center in Saudi Arabia , 2016, International Ophthalmology.

[14]  M. Schaller,et al.  Pathogenesis and clinical presentation of rosacea as a key for a symptom‐oriented therapy , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15]  M. Steinhoff,et al.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments , 2016, Advances in Therapy.

[16]  C. Cochrane,et al.  Canadian Clinical Practice Guidelines for Rosacea , 2016, Journal of cutaneous medicine and surgery.

[17]  Z. Fedorowicz,et al.  Interventions for Rosacea. , 2015, JAMA.

[18]  Amber J. Fletcher,et al.  Using the Delphi Method for Qualitative, Participatory Action Research in Health Leadership , 2014 .

[19]  D. Thiboutot,et al.  Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. , 2013, Cutis.

[20]  W. Klövekorn,et al.  Rosazea – S1‐Leitlinie , 2013 .

[21]  M. Schaller,et al.  Rosacea – S1 Guideline , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[22]  D. Keahey,et al.  Treatment options for acne rosacea. , 2009, American family physician.

[23]  M. Macsai,et al.  Standard management options for rosacea, part 1: overview and broad spectrum of care. , 2009, Cutis.

[24]  F. Powell.  Clinical practice. Rosacea. , 2005, The New England journal of medicine.

[25]  R. Odom.  The nosology of rosacea. , 2004, Cutis.

[26]  M. Dahl.  Rosacea subtypes: a treatment algorithm. , 2004, Cutis.

[27]  A. Feinstein,et al.  Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. , 2002, Journal of the American Academy of Dermatology.

[28]  U. Werneke,et al.  An evidence and consensus based guideline for acute diarrhoea management , 2001, Archives of disease in childhood.

[29]  D. Hunter,et al.  Qualitative Research: Consensus methods for medical and health services research , 1995 .

[30]  Sewon Kang,et al.  Rosacea comorbidities and future research: The 2017 update by the National Rosacea Society Expert Committee. , 2018, Journal of the American Academy of Dermatology.

[31]  Diane Thiboutot,et al.  Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee , 2018, Journal of the American Academy of Dermatology.